Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma

被引：1

作者：

Zheng, Biao ^{[1
]}

Hu, Yongxian ^{[2
,3
,4
,5
]}

Zhang, Jiqin ^{[1
]}

Zhang, Mingming ^{[2
,3
,4
,5
]}

Li, Wei ^{[1
]}

Wu, Wenjun ^{[2
,3
,4
,5
]}

Cui, Jiazhen ^{[2
,3
,4
,5
]}

Wei, Guoqing ^{[2
,3
,4
,5
]}

Du, Bing ^{[1
,6
,7
]}

Liu, Mingyao ^{[1
,6
,7
]}

Huang, He ^{[2
,3
,4
,5
]}

机构：

[1] BRL Med Inc, Shanghai, Peoples R China

[2] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China

[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Hangzhou, Peoples R China

[4] Zhejiang Univ, Liangzhu Lab, Med Ctr, Hangzhou, Peoples R China

[5] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China

[6] East China Normal Univ, Shanghai Frontiers Sci Ctr Genome Editing & Cell, Inst Biomed Sci & Sch Life Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China

[7] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-185573

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4